Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Red yeast rice + salvia miltiorrhiza + ganoderma lucidum is a natural product combination capsule developed and manufactured by Zhejiang Fangge Pharmaceutical. This oral formulation is primarily used for the management of hyperlipidemia and the promotion of cardiovascular health. The therapeutic effect is largely attributed to monacolins (such as monacolin K) present in the red yeast rice, which function as HMG-CoA reductase inhibitors to lower endogenous cholesterol production. *Salvia miltiorrhiza* (Danshen) provides additional benefits through its anti-inflammatory and anti-platelet activities, which help improve blood flow and protect the vascular endothelium. *Ganoderma lucidum* (Lingzhi) contributes immunomodulatory and antioxidant properties, supporting overall metabolic health. The product is approved in China as a health supplement (often referred to as a Blue Hat product) for regulating blood lipids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on red yeast rice + salvia miltiorrhiza + ganoderma lucidum.